Streptococcus pneumoniae (S. pneumoniae) is a commensal bacterium that causes several diseases, including non-invasive infections (such as acute sinusitis and otitis media) and invasive infections with higher mortality (such as meningitis and septicaemia). Currently, the resistance of S. pneumoniae to antibacterial drugs is very common, which undoubtedly increases the difficulty to treat S. pneumoniae infection.
Creative Biolabs has focused on the research of antibacterial drugs for many years. Thus, we are confident in offering high-quality comprehensive services to help our customers to discover more efficient antibacterial drugs to combat drug-resistant S. pneumoniae.
S. pneumoniae is a type of Gram-positive, facultatively anaerobic bacteria in the shape of slightly pointed cocci. It is a member of the genus Streptococcus. S. pneumoniae has been recognized as a major cause of bacterial pneumonia and otitis media and an important contributor to bacterial meningitis. Besides, this bacterium also causes many other types of invasive pneumococcal diseases including bronchitis, rhinitis, acute sinusitis, osteomyelitis, septic arthritis, endocarditis, peritonitis, conjunctivitis, sepsis, pericarditis, and cellulitis. In healthy people, S. pneumoniae is part of the normal upper respiratory tract flora and does not cause diseases. However, some people who have a weak immune system, such as children and the elderly, may be easily infected with S. pneumoniae. In children no older than 5 in the US, about 1,400 cases of meningitis, 17,000 cases of bloodstream infections, and 71,000 cases of pneumonia are caused by pneumonia every year.
Antibiotics, such as penicillin, ceftriaxone, and cefotaxime, are the first choice against pneumococcal infection. However, inappropriate use of antibiotics in the community may induce the evolution of antibiotic-resistant S. pneumoniae. Furthermore, S. pneumoniae possesses horizontal gene transfer, which increases the acquisition of antibiotic-resistant genes. Drug-resistant S. pneumoniae has emerged around the world, which increases the difficulty for the treatment of S. pneumoniae infections and triggers a greater risk of death. A study in Thailand has reported the prevalence of multi-drug resistance S. pneumoniae is 31.6%.
In order to effectively combat S. pneumoniae infection, it is required to develop new more efficient antibacterials. Antimicrobial peptides are promising alternatives to conventional antibiotics and expected to be used to inhibit multidrug-resistant S. pneumoniae. Currently, several AMPs have been designed and synthesized, such as chemically synthesized peptide M-Brucin and four hybrid peptides, to investigate their antibacterial activity against Streptococcus. In addition, some more potential antibacterial drug targets were found such as pneumococcal surface protein A (a well-characterized virulence factor).
Creative Biolabs is a world-leading service provider that offers a full range of antibacterial drug discovery services for global customers. We have established a comprehensive drug development platform which allows us to offer high-quality and low-cost antibacterial drug discovery services from target identification and validation, Hit identification, Hit to lead, Lead optimization, to IND enabling. Drug resistance is very common in S. pneumoniae. We also have great confidence to provide a variety of flexible solutions for antibacterial drug development against drug-resistant S. Pneumoniae.
If you are interested in our services, please don’t hesitate to contact us for more information and a detailed quote.
For Research Use Only.
